查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1953938

單核苷酸多態性基因分型市場－全球產業規模、佔有率、趨勢、機會及預測（按技術、應用、地區和競爭格局分類，2021-2031年）

Single Nucleotide Polymorphism Genotyping Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 182 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球單核苷酸多態性 (SNP) 基因分型市場預計將從 2025 年的 131.8 億美元成長到 2031 年的 340.7 億美元，複合年成長率達到 17.15%。

單核苷酸多態性（SNP）基因型鑒定是一種專門的分析方法，用於測量DNA序列特定位置的遺傳變異，從而揭示與疾病和生理特徵相關的標記。該市場的主要驅動力是全球向精準醫療的轉型以及藥物基因組學在臨床實踐中的應用，這需要精準的基因分析來實現個人化治療。根據個人化醫療聯盟（Personalized Medicine Coalition）預測，2024年將有18種新的個人化藥物核准，佔新核准治療性分子實體總數的38%。這表明基因分型技術在患者分層和現代藥物研發中扮演著至關重要的角色。

市場概覽
預測期 2027-2031
市場規模：2025年 131.8億美元
市場規模：2031年 340.7億美元
複合年成長率：2026-2031年 17.15%
成長最快的細分市場 TaqMan SNP基因型鑒定
最大的市場 北美洲

儘管成長指標積極，但該產業在敏感生物數據的管理方面仍面臨許多挑戰。其中一個關鍵挑戰是基因資料隱私和安全監管環境的嚴格性，這可能會阻礙市場發展。遵守不斷變化的國際資料保護標準的高成本和複雜的操作流程可能會成為小規模診斷檢查室的進入門檻，並限制此類服務的廣泛應用。

市場促進因素

對基因組研究和生物銀行投資的不斷成長是單核苷酸多態性（SNP）基因型鑒定市場的主要驅動力，為大規模人群研究提供了必要的資金。各國政府和私人機構正向生物樣本庫投入大量資金，以建立強大的基因資料庫，這對於檢測疾病標記和開發精準醫療至關重要。這些資金的湧入直接促進了基因型鑒定晶片和定序平台的購置，而這些設備是分析數百萬個生物樣本所必需的。例如，2024年7月，英國政府宣布英國生物樣本庫（UK Biobank）已獲得1,600萬英鎊的資金，用於升級其雲端基礎設施，以確保海量基因組資料集的安全儲存和分析。同時，Illumina公司在2024年2月報告稱，2023會計年度的全年收入將達到45億美元，反映出全球對高通量基因分析工具的強勁需求。

此外，SNP基因分型在農業生物技術領域的廣泛應用正將市場拓展至人類醫學之外。農業科學家和育種家正積極利用基因分型進行標記輔助選擇，以提高作物產量、增強抗病能力並改良牲畜性狀，從而應對全球糧食安全挑戰。這一趨勢得到了公共部門的大力支持，這些資金旨在透過基因組技術的進步實現農業現代化。根據美國農業部（USDA）國家食品與農業研究所2023年12月發布的2024會計年度通知，將提供約3億美元用於植物健康和動物育種遺傳學等研究重點領域，以促進在標準農業實踐中採用基於SNP的篩檢。

市場挑戰

全球單核苷酸多態性（SNP）基因型鑒定市場成長的主要障礙在於嚴格的基因資料隱私和安全法規結構。由於基因型鑒定分析的是高度敏感的DNA序列，用於檢測生理特徵和疾病標記物，因此該行業必須遵守複雜的國際資料保護條例網路，例如美國的HIPAA和歐洲的GDPR。這些法規對病患知情同意管理、資料加密和跨境資訊交流都制定了嚴格的標準。維持合規的高成本和營運複雜性構成了巨大的進入門檻，尤其對於缺乏大型製藥公司資金支持的研究機構和小規模診斷檢查室，這有效地限制了創新和市場競爭。

這種監管壓力迫使企業將大量資源投入法律和合規基礎建設，而非研發，直接阻礙了市場擴張。各行各業都面臨著遵守這些規定的挑戰。國際隱私專業人員協會 (IAPP) 的報告顯示，僅有 20% 的隱私專業人員對其所在機構在 2024 年繼續遵守不斷變化的隱私法律的能力充滿信心。這種不確定性阻礙了對新型基因分型舉措的投資，並減緩了精準醫療的發展，因為企業出於聲譽受損和麵臨嚴厲法律處罰的風險，對擴大業務規模仍然保持謹慎。

市場趨勢

市場正迅速轉向次世代定序(NGS) 技術，取代傳統的晶片技術，實現對新突變和已知突變的同步檢測。這項轉變提供了複雜性狀分析和精準醫療所需的精細基因組解析度。高精度定序平台的廣泛應用推動了這一趨勢，使研究人員能夠對以往難以用傳統技術分析的基因組區域進行精確的基因分型。近期硬體出貨量凸顯了這項技術發展。根據 Pacific Biosciences 截至 2025 年 2 月的會計年度財務報告，該公司在 2024 年第四季出貨了 23 套 Revio定序系統，顯示市場對高通量基因組基礎設施的需求強勁。

同時，液態生物檢體在非侵入性SNP檢測領域的應用正在變革臨床診斷。這項技術透過分析血液樣本中的遊離DNA，無需進行侵入性組織切片檢查即可檢測疾病相關突變，從而實現對癌症等疾病的持續監測。這項優勢正推動高靈敏度基因分型方法在常規患者照護中的廣泛應用。這種日益增強的整合也體現在服務量上。根據Natera公司截至2025年2月的會計年度財務報告，該公司在2024年第四季處理了約792,800份檢測，凸顯了非侵入性基因篩檢應用領域的市場顯著擴張。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球單核苷酸多態性基因分型市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依技術分類（TaqMan SNP基因型鑒定、Massarray SNP基因型鑒定、SNP GeneChip晶片、其他）
    • 按應用領域（動物遺傳學、植物改良、診斷研究、藥物和藥物基因組學、農業生物技術等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

6. 北美單核苷酸多態性基因分型市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲單核苷酸多態性基因分型市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區單核苷酸多態性基因分型市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲單核苷酸多態性基因分型市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

10. 南美洲單核苷酸多態性基因分型市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球單核苷酸多態性基因分型市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Agilent Technologies Inc.
  • Bio-Rad Laboratories Inc.
  • Danaher Corporation
  • Douglas Scientific LLC
  • Illumina Inc.
  • Life Technologies Corp.
  • Luminex Corp
  • Promega Corporation
  • Thermo Fischer Scientific Inc.
  • Fluidigm Corporation

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 21813

The Global Single Nucleotide Polymorphism Genotyping Market is projected to expand from USD 13.18 Billion in 2025 to USD 34.07 Billion by 2031, achieving a CAGR of 17.15%. Single Nucleotide Polymorphism genotyping is a specialized analytical method used to measure genetic variations at specific positions within DNA sequences to uncover markers associated with diseases or physiological traits. This market is primarily driven by the worldwide transition toward precision medicine and the integration of pharmacogenomics into clinical care, which requires precise genetic profiling for customized treatments. According to the Personalized Medicine Coalition, 18 new personalized medicines were FDA-approved in 2024, accounting for 38 percent of all newly authorized therapeutic molecular entities, highlighting the critical reliance on genotyping technologies for patient stratification and modern drug development.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 13.18 Billion
Market Size 2031USD 34.07 Billion
CAGR 2026-203117.15%
Fastest Growing SegmentTaqMan SNP Genotyping
Largest MarketNorth America

Despite these positive growth indicators, the industry confronts significant obstacles regarding the management of sensitive biological data. A primary challenge that threatens to slow market progression is the rigorous regulatory environment governing genetic data privacy and security. The high costs and operational intricacies involved in adhering to shifting international data protection standards can erect entry barriers for smaller diagnostic laboratories and restrict the broader uptake of these services.

Market Driver

Rising investments in genomic research and biobanking serve as a major driver for the Single Nucleotide Polymorphism genotyping market, supplying essential capital for extensive population studies. Governments and private organizations are allocating significant funds to biobanks to establish robust genetic databases, which are crucial for detecting disease markers and creating precision therapies. This financial influx directly facilitates the acquisition of genotyping arrays and sequencing platforms needed to analyze millions of biological samples. For instance, the UK Government announced in July 2024 that the UK Biobank secured £16 million to modernize its cloud infrastructure, ensuring the secure storage and analysis of its massive genomic dataset, while Illumina reported full-year 2023 revenue of $4.50 billion in February 2024, reflecting strong global demand for high-throughput genetic analysis tools.

Additionally, the growing application of SNP genotyping in agricultural biotechnology is broadening the market's reach beyond human healthcare. Agricultural scientists and breeders are increasingly employing genotyping for marker-assisted selection to boost crop yields, enhance disease resistance, and refine livestock traits, thereby tackling global food security issues. This shift is bolstered by substantial public sector funding designed to modernize agriculture through genomic advancements. According to the USDA National Institute of Food and Agriculture's December 2023 notification for the 2024 cycle, approximately $300 million was made available to fund research priorities such as plant health and animal breeding genetics, incentivizing the adoption of SNP-based screening in standard agricultural practices.

Market Challenge

A significant obstacle restricting the growth of the Global Single Nucleotide Polymorphism (SNP) Genotyping Market is the strict regulatory framework regarding genetic data privacy and security. Because SNP genotyping entails analyzing highly sensitive DNA sequences to detect physiological traits and disease markers, the industry must comply with a complicated network of international data protection regulations, such as HIPAA in the United States and the GDPR in Europe. These laws enforce rigorous standards for patient consent management, data encryption, and cross-border information exchanges. The associated high costs and operational complexity of maintaining compliance establish substantial barriers to entry, especially for research institutions and smaller diagnostic laboratories without the financial backing of large pharmaceutical companies, effectively limiting innovation and market competition.

This regulatory pressure directly impedes market expansion by compelling organizations to allocate significant resources toward legal and compliance infrastructures instead of research and development. The challenge of adhering to these requirements is felt throughout the sector; according to the International Association of Privacy Professionals, only 20 percent of privacy experts expressed full confidence in their organization's ability to remain compliant with evolving privacy laws in 2024. This uncertainty deters investment in new genotyping initiatives and retards the advancement of precision medicine, as companies remain cautious about scaling operations given the risks of reputational damage and severe legal penalties.

Market Trends

The market is increasingly shifting toward Next-Generation Sequencing (NGS) technologies, which are replacing traditional arrays by allowing for the simultaneous detection of both novel and known variants. This transition offers the detailed genomic resolution necessary for complex trait analysis and advanced precision medicine. The growing adoption of high-fidelity sequencing platforms supports this movement, enabling researchers to accurately genotype challenging genomic regions that earlier technologies failed to resolve. Recent hardware distributions highlight this technological evolution; according to Pacific Biosciences' February 2025 financial report, the company shipped 23 Revio sequencing systems during the fourth quarter of 2024, signaling strong demand for high-throughput genomic infrastructure.

Concurrently, the application of liquid biopsy for non-invasive SNP detection is transforming clinical diagnostics. By examining cell-free DNA from blood samples, this method enables the detection of disease-linked mutations without the need for invasive tissue biopsies, allowing for the ongoing monitoring of conditions like cancer. This capability has driven the widespread adoption of highly sensitive genotyping assays in routine patient care. The extent of this integration is reflected in service volumes; according to Natera's February 2025 financial results, the company processed approximately 792,800 tests in the fourth quarter of 2024, emphasizing the significant market expansion in non-invasive genetic screening applications.

Key Market Players

  • Agilent Technologies Inc.
  • Bio-Rad Laboratories Inc.
  • Danaher Corporation
  • Douglas Scientific LLC
  • Illumina Inc.
  • Life Technologies Corp.
  • Luminex Corp
  • Promega Corporation
  • Thermo Fischer Scientific Inc.
  • Fluidigm Corporation

Report Scope

In this report, the Global Single Nucleotide Polymorphism Genotyping Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Single Nucleotide Polymorphism Genotyping Market, By Technology

  • TaqMan SNP Genotyping
  • Massarray SNP Genotyping
  • SNP GeneChip Arrays
  • Others

Single Nucleotide Polymorphism Genotyping Market, By Application

  • Animal Genetics
  • Plant Improvement
  • Diagnostic Research
  • Pharmaceuticals and Pharmacogenomics
  • Agricultural Biotechnology
  • Others

Single Nucleotide Polymorphism Genotyping Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Single Nucleotide Polymorphism Genotyping Market.

Available Customizations:

Global Single Nucleotide Polymorphism Genotyping Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Single Nucleotide Polymorphism Genotyping Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Technology (TaqMan SNP Genotyping, Massarray SNP Genotyping, SNP GeneChip Arrays, Others)
    • 5.2.2. By Application (Animal Genetics, Plant Improvement, Diagnostic Research, Pharmaceuticals and Pharmacogenomics, Agricultural Biotechnology, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Single Nucleotide Polymorphism Genotyping Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Technology
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Single Nucleotide Polymorphism Genotyping Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Technology
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Single Nucleotide Polymorphism Genotyping Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Technology
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Single Nucleotide Polymorphism Genotyping Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Technology
        • 6.3.3.2.2. By Application

7. Europe Single Nucleotide Polymorphism Genotyping Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Technology
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Single Nucleotide Polymorphism Genotyping Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Technology
        • 7.3.1.2.2. By Application
    • 7.3.2. France Single Nucleotide Polymorphism Genotyping Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Technology
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Single Nucleotide Polymorphism Genotyping Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Technology
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Single Nucleotide Polymorphism Genotyping Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Technology
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Single Nucleotide Polymorphism Genotyping Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Technology
        • 7.3.5.2.2. By Application

8. Asia Pacific Single Nucleotide Polymorphism Genotyping Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Technology
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Single Nucleotide Polymorphism Genotyping Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Technology
        • 8.3.1.2.2. By Application
    • 8.3.2. India Single Nucleotide Polymorphism Genotyping Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Technology
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Single Nucleotide Polymorphism Genotyping Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Technology
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Single Nucleotide Polymorphism Genotyping Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Technology
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Single Nucleotide Polymorphism Genotyping Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Technology
        • 8.3.5.2.2. By Application

9. Middle East & Africa Single Nucleotide Polymorphism Genotyping Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Technology
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Single Nucleotide Polymorphism Genotyping Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Technology
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Single Nucleotide Polymorphism Genotyping Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Technology
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Single Nucleotide Polymorphism Genotyping Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Technology
        • 9.3.3.2.2. By Application

10. South America Single Nucleotide Polymorphism Genotyping Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Technology
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Single Nucleotide Polymorphism Genotyping Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Technology
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Single Nucleotide Polymorphism Genotyping Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Technology
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Single Nucleotide Polymorphism Genotyping Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Technology
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Single Nucleotide Polymorphism Genotyping Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Agilent Technologies Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Bio-Rad Laboratories Inc.
  • 15.3. Danaher Corporation
  • 15.4. Douglas Scientific LLC
  • 15.5. Illumina Inc.
  • 15.6. Life Technologies Corp.
  • 15.7. Luminex Corp
  • 15.8. Promega Corporation
  • 15.9. Thermo Fischer Scientific Inc.
  • 15.10. Fluidigm Corporation

16. Strategic Recommendations

17. About Us & Disclaimer